Metformin attenuates graft-versus-host disease via restricting mammalian target of rapamycin/signal transducer and activator of transcription 3 and promoting adenosine monophosphate–activated protein kinase-autophagy for the balance between T helper 17 and Tregs

Translational Research

Volumn 173, Issue , 2016, Pages 115-130

  Park, Min Jung ^a   Lee, Seon Yeong ^a   Moon, Su Jin ^a   Son, Hye Jin ^a   Lee, Sung Hee ^a   Kim, Eun Kyung ^a   Byun, Jae Kyeong ^a   Shin, Dong Yun ^b   Park, Sung Hwan ^a   Yang, Chul Woo ^c   Cho, Mi La ^a  

^a The Catholic University of Korea   (South Korea)

^b Gachon University   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PROTEIN SERINE THREONINE KINASE; STAT3 PROTEIN; UNCLASSIFIED DRUG; ADENYLATE KINASE; TARGET OF RAPAMYCIN KINASE;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; LETHALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REDUCTION (CHEMISTRY); REGULATORY T LYMPHOCYTE; SPLEEN CELL; TH17 CELL; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; GRAFT VS HOST DISEASE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SPLEEN;

ADENYLATE KINASE; ANIMALS; AUTOPHAGY; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENZYME ACTIVATION; GRAFT VS HOST DISEASE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; METFORMIN; MICE, INBRED BALB C; MICE, INBRED C57BL; PHOSPHORYLATION; SPLEEN; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TOR SERINE-THREONINE KINASES;

EID: 84965036015     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2016.03.006     Document Type: Article

References (48)

1. 1 Shlomchik, W.D., Graft-versus-host disease. Nat Rev Immunol 7 (2007), 340–352.
2. 2 Gerriets, V.A., Rathmell, J.C., Metabolic pathways in T cell fate and function. Trends Immunol 33 (2012), 168–173.
3. 3 Fox, C.J., Hammerman, P.S., Thompson, C.B., Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol 5 (2005), 844–852.
4. 4 Kahn, B.B., Alquier, T., Carling, D., et al. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1 (2005), 15–25.
5. 5 Zhou, G., Myers, R., Li, Y., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108 (2001), 1167–1174.
6. 6 Hardie, D.G., AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8 (2007), 774–785.
7. 7 Bolster, D.R., Crozier, S.J., Kimball, S.R., et al. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 277 (2002), 23977–23980.
8. 8 Chi, H., Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol 12 (2012), 325–338.
9. 9 Ge, W., Ren, J., mTOR-STAT3-notch signalling contributes to ALDH2-induced protection against cardiac contractile dysfunction and autophagy under alcoholism. J Cell Mol Med 16 (2012), 616–626.
10. 10 Hirsch, H.A., Iliopoulos, D., Struhl, K., Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A 110 (2013), 972–977.
11. 11 Yokogami, K., Wakisaka, S., Avruch, J., et al. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 10 (2000), 47–50.
12. 12 Nath, N., Khan, M., Paintlia, M.K., et al. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol 182 (2009), 8005–8014.
13. 13 Park, C.S., Bang, B.R., Kwon, H.S., et al. Metformin reduces airway inflammation and remodeling via activation of AMP-activated protein kinase. Biochem Pharmacol 84 (2012), 1660–1670.
14. 14 Tsoyi, K., Jang, H.J., Nizamutdinova, I.T., et al. Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol 162 (2011), 1498–1508.
15. 15 Shi, W.Y., Xiao, D., Wang, L., et al. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis, 3, 2012, e275.
16. 16 Fukui, J., Inaba, M., Ueda, Y., et al. Prevention of graft-versus-host disease by intra-bone marrow injection of donor T cells. Stem Cells 25 (2007), 1595–1601.
17. 17 Schalm, S.S., Fingar, D.C., Sabatini, D.M., et al. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol 13 (2003), 797–806.
18. 18 Nojima, H., Tokunaga, C., Eguchi, S., et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 278 (2003), 15461–15464.
19. 19 Wouters, B.G., Koritzinsky, M., Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8 (2008), 851–864.
20. 20 Amer, J., Weiss, L., Reich, S., et al. The oxidative status of blood cells in a murine model of graft-versus-host disease. Ann Hematol 86 (2007), 753–758.
21. 21 Nguyen, T., Nioi, P., Pickett, C.B., The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 284 (2009), 13291–13295.
22. 22 Chen, J., Shi, X., Padmanabhan, R., et al. Identification of novel modulators of mitochondrial function by a genome-wide RNAi screen in Drosophila melanogaster. Genome Res 18 (2008), 123–136.
23. 23 Jones, R.G., Plas, D.R., Kubek, S., et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18 (2005), 283–293.
24. 24 Ryan, K.M., p53 and autophagy in cancer: guardian of the genome meets guardian of the proteome. Eur J Cancer 47 (2011), 44–50.
25. 25 Teshima, T., Maeda, Y., Ozaki, K., Regulatory T cells and IL-17-producing cells in graft-versus-host disease. Immunotherapy 3 (2011), 833–852.
26. 26 Deng, X.S., Wang, S., Deng, A., et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 11 (2012), 367–376.
27. 27 Sambol, N.C., Chiang, J., O'Conner, M., et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 36 (1996), 1012–1021.
28. 28 Zheng, J., Liu, Y., Liu, Y., et al. Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice. Sci Transl Med, 5, 2013, 168ra9.
29. 29 Feng, Z., Zhang, H., Levine, A.J., et al. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 102 (2005), 8204–8209.
30. 30 Viollet, B., Guigas, B., Sanz Garcia, N., et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 122 (2012), 253–270.
31. 31 Majhail, N.S., Challa, T.R., Mulrooney, D.A., et al. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 15 (2009), 1100–1107.
32. 32 Baker, K.S., Ness, K.K., Steinberger, J., et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood 109 (2007), 1765–1772.
33. 33 Engelhardt, B.G., Jagasia, S.M., Crowe, J.E. Jr., et al. Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity. Blood 119 (2012), 2417–2421.
34. 34 Nerstedt, A., Johansson, A., Andersson, C.X., et al. AMP-activated protein kinase inhibits IL-6-stimulated inflammatory response in human liver cells by suppressing phosphorylation of signal transducer and activator of transcription 3 (STAT3). Diabetologia 53 (2010), 2406–2416.
35. 35 Brodowska, K., Theodoropoulou, S., Meyer Zu Horste, M., et al. Effects of metformin on retinoblastoma growth in vitro and in vivo. Int J Oncol 45 (2014), 2311–2324.
36. 36 Michalek, R.D., Gerriets, V.A., Jacobs, S.R., et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol 186 (2011), 3299–3303.
37. 37 Mihaylova, M.M., Shaw, R.J., The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 13 (2011), 1016–1023.
38. 38 Witters, L.A., The blooming of the French lilac. J Clin Invest 108 (2001), 1105–1107.
39. 39 Bailey, C.J., Turner, R.C., Metformin. N Engl J Med 334 (1996), 574–579.
40. 40 Scarpello, J.H., Improving survival with metformin: the evidence base today. Diabetes Metab, 29, 2003 6S36–6S43.
41. 41 Libby, G., Donnelly, L.A., Donnan, P.T., et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32 (2009), 1620–1625.
42. 42 Ho, V.T., Soiffer, R.J., The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98 (2001), 3192–3204.
43. 43 Edinger, M., Hoffmann, P., Ermann, J., et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9 (2003), 1144–1150.
44. 44 Brimnes, J., Allez, M., Dotan, I., et al. Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol 174 (2005), 5814–5822.
45. 45 Sugita, S., Futagami, Y., Horie, S., et al. Transforming growth factor beta-producing Foxp3(+)CD8(+)CD25(+) T cells induced by iris pigment epithelial cells display regulatory phenotype and acquire regulatory functions. Exp Eye Res 85 (2007), 626–636.
46. 46 Sugita, S., Ng, T.F., Lucas, P.J., et al. B7+ iris pigment epithelium induce CD8+ T regulatory cells; both suppress CTLA-4+ T cells. J Immunol 176 (2006), 118–127.
47. 47 Zheng, S.G., Wang, J.H., Koss, M.N., et al. CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J Immunol 172 (2004), 1531–1539.
48. 48 Jarvis, L.B., Matyszak, M.K., Duggleby, R.C., et al. Autoreactive human peripheral blood CD8+ T cells with a regulatory phenotype and function. Eur J Immunol 35 (2005), 2896–2908.